Liver transplantation has become standard practice for treating end-stage liver disease. The success of the procedure relies on effective immunosuppressive medications to control the host's immune response. Despite the liver's inherent capacity to foster tolerance, the early post-transplant period is marked by significant immune reactivity. To ensure favorable outcomes, it is imperative to identify and manage various rejection types, encompassing T-cell-mediated, antibody-mediated, and chronic rejection. However, the approach to prescribing immunosuppressants relies heavily on clinical judgment rather than evidence-based criteria. Given that the majority of patients will require lifelong immuno suppression as the mechanisms underlying operational tolerance are still being investigated, healthcare providers must possess an understanding of immune responses, rejection mechanisms, and the pathways targeted by immunosuppressive drugs. This knowledge enables customization of treatments and improved patient care, even though a consensus on an optimal immunosuppressive regimen remains elusive.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10989464PMC
http://dx.doi.org/10.5500/wjt.v14.i1.89772DOI Listing

Publication Analysis

Top Keywords

immunology demystified
4
demystified guide
4
guide transplant
4
transplant hepatologists
4
hepatologists liver
4
liver transplantation
4
transplantation standard
4
standard practice
4
practice treating
4
treating end-stage
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!